Evidence map›Paper›PMID 39041702›Full record

ArticleImmunotherapy2024

Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation.

Anna Babayan, Evgeny Ledin, Alexandra Lebedeva, Olesya Kuznetsova, Daria Kravchuk, Tatiana Grigoreva, Ekaterina Belova, Alexandra Kavun, Vladislav Mileyko, Alexey Tryakin and 2 more

Abstract readCase Reports
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna BabayanClinical Hospital 2, MEDSI, Moscow, 119071, Russia.
Evgeny LedinClinical Hospital 2, MEDSI, Moscow, 119071, Russia.
Alexandra LebedevaOncoAtlas LLC, Moscow, 119049, Russia.ORCID 0000-0003-1920-5076
Olesya KuznetsovaOncoAtlas LLC, Moscow, 119049, Russia.
Daria KravchukState Budgetary Institution of Healthcare of the City of Moscow "Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Health of the City of Moscow, Moscow, 142770, Russian Federation.
Tatiana GrigorevaOncoAtlas LLC, Moscow, 119049, Russia.
Ekaterina BelovaOncoAtlas LLC, Moscow, 119049, Russia.
Alexandra KavunOncoAtlas LLC, Moscow, 119049, Russia.
Vladislav MileykoOncoAtlas LLC, Moscow, 119049, Russia.
Alexey TryakinN.N. Blokhin Russian Cancer Research Center, Moscow, 115478, Russia.
Mikhail FedyaninN.N. Blokhin Russian Cancer Research Center, Moscow, 115478, Russia.
Maxim IvanovOncoAtlas LLC, Moscow, 119049, Russia.

Funding

Russian Science Foundation 22-75-10154 (https://rscf.ru/project/22-75-10154/)
6 · The paper itself

Abstract

Microsatellite instability (MSI) is an important biomarker in cancer. While routine methods can detect MSI in certain tumor types, in other tumor types the results may be incorrect due to differences in the MSI loci pattern. Here, we report the case of a patient with pancreatic adenocarcinoma, with confirmed MSI by two independent next-generation sequencing tests, but not by routine methods, who had progression on pembrolizumab. Comparison of the patient's MSI loci patterns with MSI+ colorectal adenocarcinoma samples showed a lower fraction of unstable loci, low resolution of a second peak in the repeat length spectrum of unstable short tandem repeats in the patient's sample, and a lower length of indels (3.7 vs 4.5 base pairs,

Indexed as

AdenocarcinomaImmune Checkpoint InhibitorsMicrosatellite InstabilityPancreatic NeoplasmsAntibodies, Monoclonal, HumanizedHigh-Throughput Nucleotide SequencingHumansMicrosatellite RepeatsMutationAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumabcase reportimmune checkpoint inhibitorsliquid biopsymicrosatellite instabilitynext generation sequencing

Identifiers

PMID39041702
PMCPMC11457661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.